Found: 5
Select item for more details and to access through your institution.
Alemtuzumab-based reduced-intensity conditioning allogeneic tranplantation for myeloma and plasma cell leukemia -- a single institution experience.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Alemtuzumab-Based Reduced-Intensity Conditioning Allogeneic Transplantation for Myeloma and Plasma Cell Leukemia - A Single- Institution Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2011, v. 11, n. 2, p. 242, doi. 10.1016/j.clml.2011.03.004
- By:
- Publication type:
- Article
Rituximab and thalidomide combination therapy for Castleman disease.
- Published in:
- British Journal of Haematology, 2012, v. 158, n. 3, p. 421, doi. 10.1111/j.1365-2141.2012.09157.x
- By:
- Publication type:
- Article
Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease.
- Published in:
- British Journal of Haematology, 2011, v. 155, n. 5, p. 632, doi. 10.1111/j.1365-2141.2011.08754.x
- By:
- Publication type:
- Article
The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.
- Published in:
- British Journal of Haematology, 2010, v. 150, n. 3, p. 326, doi. 10.1111/j.1365-2141.2010.08250.x
- By:
- Publication type:
- Article